Skip to main content

Day: May 24, 2022

Digital PCR Market: USD 799.1 Million by 2028 at CAGR of 17.2%

According to Fortune Business Insights, the global Digital PCR Market size is projected to reach USD 799.1 Million in 2028, at CAGR of 17.2% during forecast period; Rising Utilization of Biomarkers is Expected to Augment Growth Pune, India, May 24, 2022 (GLOBE NEWSWIRE) — The global digital PCR market size is prophesied to reach USD 799.1 million by the end of 2028 on account of the increasing adoption of dPCR over real-time PCR. Digital PCR or polymerase chain reaction is a method of measuring RNA or DNA present in a sample in a reproducible manner. They are used for amplification and quantification of nucleic acids. According to a recently published report by Fortune Business Insights titled, “Digital PCR Market Size, Share & Industry Analysis, By Type (Droplet Digital PCR, Chip-based Digital PCR, and Others), By Product...

Continue reading

Form 8.3 – Capital & Counties Properties Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1.        KEY INFORMATION  (a)        Full name of discloser: Investec Wealth & Investment Limited(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeCapital & Counties Properties Plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)        Date...

Continue reading

SP Group A/S – Interim Report – First quarter of 2022

SP Group generated revenue of DKK 720.1 million in the Q1 2022 reporting period, a 20.4% improvement from DKK 598.1 million in Q1 2021. EBITDA was up by 23.3% to DKK 129.7 million from DKK 105.2 million last year, and profit before tax was up 22.9% to DKK 83.0 million. FY 2022 guidance maintained. SP Group expects FY 2022 revenue to grow by 5-15% with an EBITDA margin of 16-18% and an EBT margin of 9-12%. See attached company announcement no. 35/2022.AttachmentMeddelelse nr. 35 – Q1 – ENG – 24 05 22

Continue reading

AppTech Payments Corp. Closes the Acquisition of Hothand and their Powerful Patent Portfolio

CARLSBAD, Calif., May 24, 2022 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech”) (NASDAQ: APCX), a Fintech company powering commerce experiences, is excited to announce the closing of its acquisition of Hothand Inc. (“Hothand”), a patent holding company that owns the intellectual property rights to a patent portfolio that broadly covers geofence triggered ecommerce and/or advertising via cell phone. The purchase price was a combination of cash and stock, to be disbursed upon predetermined revenue milestones. AppTech now owns Hothand’s portfolio of twelve patents including USPTO 7,693,752; USPTO 8,554,632; USPTO 8,799,102; USPTO 9,436,956; USPTO 10,102,556; USPTO 10,127,592; USPTO 10,600,094; USPTO 10,621,639; USPTO 10,846,726; USPTO 10,846,727; USPTO 10,909,593; USPTO 11,107,140. These patents are focused...

Continue reading

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

MannKind celebrates that the FDA has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder Tyvaso DPI™ production is underway at MannKind Corporation (Nasdaq: MNKD) in Danbury, Conn. On May 24, 2022, MannKind celebrated that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder. Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s innovative Technosphere® inhalation technology. MannKind and United Therapeutics (Nasdaq: UTHR) entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI.Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technology First approval of a dry powder inhaled treatment...

Continue reading

HONKARAKENNE OYJ REINSTATES ITS FINANCIAL GUIDANCE FOR 2022

HONKARAKENNE OYJ                 Insider information May 24, 2022 at 13:00 HONKARAKENNE OYJ REINSTATES ITS FINANCIAL GUIDANCE FOR 2022 At the meeting held on May 23, 2022, Honkarakenne Oyj’s Board of Directors decided to issue new financial guidelines for 2022. Honkarakenne Oyj withdrew its financial guidance for 2022 in a stock exchange release on March 1, 2022 due to the uncertainty caused by the war in Ukraine and the suspension of sales in Russia. Honkarakenne Oyj’s outlook for the rest of the year has become clearer and this allows restoring the guidance for the year 2022. At its meeting on May 23, 2022, the Board of Directors decided to reinstate its financial guidance. New guidance for 2022 Honkarakenne’s outlook is that revenue (net sales) will increase from the previous year and profit before taxes will be at the previous...

Continue reading

Constellium Posts Annual Ordinary General Meeting Materials

PARIS, May 24, 2022 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) (the “Company”) today announced that the notice and agenda and other documents for the Company’s Annual Ordinary General Meeting of Shareholders to be held on June 10, 2022, at 16:00 CET (10:00 AM EDT), are available on its website at www.constellium.com and will be available free of charge at the offices of the Company by contacting the Corporate Secretary at cstm.corporatesecretary@constellium.com. About Constellium Constellium (NYSE: CSTM) is a global sector leader that develops innovative, value added aluminium products for a broad scope of markets and applications, including aerospace, automotive and packaging. Constellium generated €6.2 billion of revenue in 2021.Jason Hershiser – Investor RelationsPhone: +1 443 988 0600investor-relations@constellium.com Delphine...

Continue reading

Verde Announces Plans for First Distribution of Gains and Restructure

Return Expected to Be a Minimum of C$10 Million to Shareholders for FY 2022 While Keeping a Minimum of C$30 Million in the Company, Restructure Expected to Increase Markets for Verde BELO HORIZONTE, Brazil, May 24, 2022 (GLOBE NEWSWIRE) — Verde AgriTech Plc (TSX: “NPK”) (OTCQB: “AMHPF”) (“Verde” or the “Company”) is pleased to announce the findings of the Independent Special Committee of the Board of Directors (the “Committee”) to re-domicile Verde to Singapore (the “Re-domiciliation”) to deliver commercial freedoms and benefits. The Committee believes the Re-domiciliation is in the best interests of Verde’s future commercial success, with access to new markets, while helping in the implementation of the Paid for Growth (“P4G”) strategy, a cornerstone program aimed at distributing gains to shareholders while maintaining Verde’s...

Continue reading

Check Point Software Technologies Achieves New Common Criteria Certification to Meet the Security Requirements for Governments Worldwide

Check Point Quantum Network Security R81 receives a common criteria certification in compliance with approved community Protection Profiles SAN CARLOS, Calif., May 24, 2022 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, is proud to announce the successful completion of a new Common Criteria (CC) certification. This achievement marks the important recognition of Check Point’s ability to meet or exceed the security requirements of the 31 Nations who are members of the Common Criteria Recognition Agreement (CCRA). Purchase decisions by Government and closely related industry, including critical infrastructure often require certification through Common Criteria. Common Criteria certification is recognized by Governments around the world as the standard...

Continue reading

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

– EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician Global Assessment (PGA) score with 36% of patients versus 6% in vehicle in PSOARING 1 and 40% of patients versus 6% in vehicle in PSOARING 2 achieving clear or almost clear with a minimum 2-grade improvement at week 12 (p

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.